register

News & Trends - MedTech & Diagnostics

J&J led largest medtech M&A in 2022

Health Industry Hub | January 20, 2023 |

MedTech News: Johnson & Johnson’s $17bn acquisition accounted for 42% of medtech M&A spend last year.

Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment. The acquisition adds heart recovery solutions to complement the company’s Biosense Webster electrophysiology business, supporting the company’s expansion in high-growth markets. 

The size and the target of this deal caught the company “off guard”. However, the organisation believes Abiomed is a “high-quality target and fits JNJ’s businesses and company culture well”.

J&J said the acquisition is expected to be slightly dilutive to earnings per share in the first year, then adding $0.05 per share in 2024 and increasingly accretive thereafter.

Interestingly, J&J’s Abiomed takeout was the second-largest in the overall life sciences sector, behind only Amgen’s $28bn acquisition of Horizon, which specialises in medicines for rare and autoimmune diseases.

In comparison, the largest deal Medtronic closed last year involved the sinusitis specialist Intersect ENT at $1.2bn.

One deal is already on the books for 2023 with Thermo Fisher’s £2.3bn ($2.8bn) purchase of The Binding Site earlier this month.

Other big groups that have expressed an interest in buying include Abbott and Medtronic, although they are mostly focused on sub-$1bn tuck-in deals.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.